Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 9/20 | 0.56 |
| ▸ | EHMT1 | Q9H9B1 | 9/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
| ▸ | SRC | P12931 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2748129 | 0.87 | EHMT2 (0.74) | EHMT2EHMT1SRC | |
| SCHEMBL8526894 | 0.86 | EHMT2 (0.76) | EHMT2EHMT1 | |
| SCHEMBL29636829 | 0.86 | EHMT2 (0.76) | EHMT2EHMT1 | |
| Hydrochloric Acid SCHEMBL6433786 | 0.85 | EHMT2 (0.74) | EHMT2EHMT1 | |
| SCHEMBL4664563 | 0.84 | EHMT2 (0.52) | EHMT2EHMT1HRH3SRCALDH1A1 | |
| SCHEMBL15960728 | 0.84 | KDR (0.51) | EHMT2EHMT1SRC | |
| SCHEMBL10102456 | 0.82 | EGFR (0.49) | EHMT2EHMT1CYP2D6CYP2C19SRC | |
| SCHEMBL15960726 | 0.81 | TLR8 (0.40) | EHMT2EHMT1SRCALDH1A1KDM4E | |
| SCHEMBL11953085 | 0.81 | EGFR (0.48) | EHMT2EHMT1CYP2D6CYP2C19SRC | |
| SCHEMBL2746706 | 0.80 | EHMT2 (0.67) | EHMT2EHMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150133460-A1 | LACTATE SALT OF 4-[6-METHOXY-7-(3-PIPERIDIN-1-YL-PROPOXY)QUINAZOLIN-4-YL]PIPERAZINE-1-CARBOXYLIC ACID(4-ISOPROPOXYPHENYL)-AMIDE AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CANCER AND OTHER DISEASES OR DISORDERS | MILLENNIUM PHAMACEUTICALS, INC. (US) | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133460-A1 | LACTATE SALT OF 4-[6-METHOXY-7-(3-PIPERIDIN-1-YL-PROPOXY)QUINAZOLIN-4-YL]PIPERAZINE-1-CARBOXYLIC ACID(4-ISOPROPOXYPHENYL)-AMIDE AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CANCER AND OTHER DISEASES OR DISORDERS | GLS, GLS2, GOT2 | EHMT2 4355/4885EHMT1 4429/4885CYP2D6 856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.